Dublin, Ireland, April 13, 2016 – Inflection Biosciences Ltd, a private company developing highly innovative treatments for cancer, today announced that data on IBL-202, a pan-PIM/pan-PI3K inhibitor, and IBL-301, a pan-PIM/pan-PI3K/mTOR inhibitor, in pre-clinical models of pancreatic cancer, will be highlighted in a poster presentation at the American Association for Cancer Research Annual Meeting 2016 which is being held at the Ernest N. Morial Convention Center in New Orleans, Louisiana, from April 16-20, 2016.
The pre-clinical data was generated through a collaboration between Inflection Biosciences Ltd. and a team of researchers led by Dr. Jonathan Brody at Thomas Jefferson University, Philadelphia, and between Inflection Biosciences Ltd. and the laboratory of Dr. Antonio Baines at North Carolina Central University in Durham, North Carolina.
The details for the poster presentation are as follows:
Date & Time: 1.00 pm – 5.00 pm Sunday 17th April, 2016
Poster Title: Novel pan-PIM/pan-PI3K/mTOR inhibitors are highly active in preclinical models of pancreatic ductal adenocarcinoma
Presenter: Dr. Kevin O’Hayer
Abstract Number: 394
Session Title: PI3K/AKT Inhibitors
Session Category: Experimental and Molecular Therapeutics
Location: Section 19, Poster Board No. 26
The full abstract can be viewed here.
About PIM/PI3 kinase inhibitors
The PI3K/AKT pathway is commonly activated in human cancer. Multiple small-molecule inhibitors have been developed to target PI3K/mTOR or AKT kinases, but the efficacy of these drugs is compromised by the stimulation of compensatory signaling pathways. One example of such compensatory pathways is that driven by PIM kinases, which produce parallel oncogenic signals to AKT and mTOR and share several downstream molecular targets. Therefore, combined inhibition of such activities in a single molecule might have the potential to achieve better clinical efficacy and prevent/suppress resistance in comparison with classical PI3K/AKT/mTOR inhibitors.
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises IBL-202 (PIM/PI3K inhibitor) and IBL-301 (PIM/PI3K/mTOR inhibitor), selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (highly selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com